Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Double-blind, Randomized, Placebo-controlled, Study to Evaluate the Safety and Immunogenicity of AERAS-456 in HIV Negative Adults Successfully Treated for Drug-susceptible Pulmonary Tuberculosis

NCT02375698 is registered in ClinicalTrials.gov with Aeras as lead sponsor.

NCT NCT02375698
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02375698 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Double-blind, Randomized, Placebo-controlled, Study to Evaluate the Safety and Immunogenicity of AERAS-456 in HIV Negative Adults Successfully Treated for Drug-susceptible Pulmonary Tuberculosis
Lead sponsor
Aeras
Phase
Phase 1
Overall status
Completed
Start date
November 21, 2014
Completion date
October 24, 2016
Enrollment
22 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

tuberculosis